Provectus Biopharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference
September 08 2016 - 6:00AM
Business Wire
Presentation Scheduled for 3 PM Eastern,
Tuesday, September 13, 2016
Conference at Lotte New York Palace Hotel,
September 11-13, 2016
Provectus Biopharmaceuticals, Inc. (NYSE
MKT:PVCT, www.provectusbio.com), a clinical-stage oncology and
dermatology biopharmaceutical company ("Provectus" or “The
Company”), today announced that it will present at Rodman &
Renshaw’s 18th Annual Global Investment Conference.
Interim CEO Peter Culpepper is scheduled to make the
presentation on Tuesday, September 13, 2016 at 3:00-3:25 PM. He
will speak in Kennedy II ballroom which is located on the fourth
floor of the Lotte New York Palace Hotel.
The conference will run from September 11-13, 2016. The
presentation will be webcast live through the following link:
http://wsw.com/webcast/rrshq26/pvct
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals is investigating
new therapies for the treatment of skin cancer, liver cancer and
breast cancer. Provectus’ investigational oncology drug, PV-10, is
an ablative immunotherapy under investigation in solid tumor
cancers. The Company has received orphan drug designations from the
FDA for its melanoma and hepatocellular carcinoma indications.
PH-10, its topical investigational drug for dermatology, is
undergoing clinical testing for psoriasis and atopic dermatitis.
Provectus has completed Phase 2 trials of PV-10 as a therapy for
metastatic melanoma, and of PH-10 as a topical treatment for atopic
dermatitis and psoriasis. Information about these and the Company's
other clinical trials can be found at the NIH registry,
www.clinicaltrials.gov. For additional information about Provectus,
please visit the Company's website at www.provectusbio.com or contact Porter, LeVay
& Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2015) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our investigational drug product for melanoma and other
solid tumors such as cancers of the liver, if such licensure is
appropriate considering the timing and structure of such a license,
or to commercialize PV-10 on our own to treat melanoma and other
solid tumors such as cancers of the liver;
- our ability to license PH-10, our
investigational drug product for dermatology, on the basis of our
phase 2 atopic dermatitis and psoriasis results, which are in the
process of being further developed in conjunction with mechanism of
action studies; and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160908005198/en/
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper,
866-594-5999 #30Interim CEO, COOorPorter, LeVay & Rose,
Inc.Marlon Nurse, 212-564-4700DM, SVP – Investor RelationsorAllison
+ PartnersTodd Aydelotte, 646-428-0644Managing Director – Media
Relations
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024